等待開盤 06-02 09:30:00 美东时间
-0.045
-0.84%
Bausch Health Companies (NYSE:BHC) raises FY2026 sales outlook from $10.625 billion-$10.875 billion to $10.670 billion-$10.920 billion vs $10.595 billion estimate.
04-30 04:09
Companies Reporting Before The Bell • Extreme Networks (NASDAQ:EXTR) is likely ...
04-29 19:11
RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and lowers the price target from $10 to $9.
04-27 23:28
Bausch Health publishes 2025 annual report Bausch Health published its annual report for fiscal year 2025, citing 11th straight quarter of year-over-year growth. Company refinanced USD 9.6 billion of debt to extend maturities and boost financial flexibility. DURECT acquisition added late-stage hepat
04-10 22:30
今日重点评级关注:巴克莱:维持Vir Biotechnology"超配"评级,目标价从26美元升至30美元;巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从10美元升至11美元
02-26 09:30
Barclays analyst Glen Santangelo maintains Bausch Health Companies (NYSE:BHC) with a Equal-Weight and lowers the price target from $8 to $7.
02-25 23:44
Solta Medical Launches Clear + Brilliant Touch Laser in Canada Solta Medical, Bausch Health Companies Inc.’s aesthetics business, launched the Clear + Brilliant Touch laser in Canada. The dual-wavelength system, approved by Health Canada on May 20, 2025, is indicated for general skin resurfacing and
02-23 21:06
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Bausch Health业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **2025年第四季度业绩(不含Bausch + Lomb):** - 营收:14.0亿美元,同比增长9%(报告基础),有机增长5% - 调整后EBITDA:7.73亿美元,同比增长9%,超出内部指引 - 调整后经营现金流:3.62亿美元,同比下降2500万美元 **2025年全年业绩(不含Bausch + Lomb):** - 营收:同比增长7%(报告基础),有机增长6% - 调整后EBITDA:实现双位数增长,超过10% - 调整后经营现金流:超过10亿美元
02-19 12:09
Bausch Health Companies (BHC) is down ~4% in after-hours trading Wednesday after posting Q4 2025 financial results that missed on the bottom line. Bausch posted GAAP EPS of ($0.30). The Street was exp...
02-19 06:19